FTC Targets PBMs In Lawsuit On Insulin Rebates But Says Pharma Also Culpable

Although the FTC’s administrative complaint focuses only on insulins, the commission hopes it will have a broader impact by driving reforms of rebate and contracting practices for other drugs as well.